Thymic carcinoma (TC) is a rare cancer and patients failing initial chemotherapy
(relapse/refractory) face limited therapeutic options given no approved options or consensus …

Background Thymic carcinomas (TCs) are rare aggressive tumors with no standard first‐line
treatment. This study was conducted to determine the optimal chemotherapy regimen for …

Simple Summary Thymic carcinoma is identified as thoracic neoplasm having low sensitivity
to systemic chemotherapy. As first-line setting, platinum-based chemotherapy is …

Objective For rarity of thymic carcinoma, no definitive chemotherapeutic regimen has been
established in second-or further-line settings. The aim of this study was to evaluate the …

Background Clinical efficacy of second-and later-line chemotherapy for patients with thymic
carcinoma previously treated with chemotherapy remains uncertain; limited data are …

Platinum-based chemotherapy is the de facto standard treatment for metastatic or
unresectable thymic carcinoma. The optimal chemotherapy regimen has not yet been …

Background The prognostic factors and the efficacy of first‐line chemotherapy remain
unclear in patients with advanced thymic carcinoma. Materials and Methods We conducted …

Introduction Thymic carcinoma (TC) is an exceptionally rare form of tumor that differs from
thymoma by virtue of its very poor prognosis. The difficulties associated with conducting …

Background Thymic carcinoma is a rare disease with an incidence of around 0.5 cases per
million with a poor prognosis. The aim of this study was to assess patient outcomes with …

Thymic carcinoma (TC) is a rare cancer with minimal evidence of survival following palliative‐
intent chemotherapy. Sunitinib, everolimus, and pembrolizumab have been proposed as …